Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …

Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …

PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

Background Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with
efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …

Bruton tyrosine kinase (BTK) inhibitors have improved chronic lymphocytic leukemia (CLL)
outcomes and offer a chemotherapyfree option [1]. The BTK inhibitor ibrutinib, alone or with …

Background Venetoclax plus obinutuzumab has been established as a fixed-duration
treatment regimen for patients with chronic lymphocytic leukaemia. We compared the long …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …